GlassScriptPhysician profile
Michelle L Raphael
NPI 1023243813
$19,118.62
in general payments reported to CMS, 2019-2025
75 companies · $49.93 in 2025
The $49.93 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,434 · 2020: $3,064 · 2021: $3,317 · 2022: $3,095 · 2023: $4,281 · 2024: $1,877 · 2025: $49.93.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,155 · Education: $53.46.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,155.12 |
| Education | $53.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,651.54 | 2019-2024 | |
| Ucb, INC. | $1,590.31 | 2019-2024 | Briviact, Nayzilam, Rystiggo |
| Novartis Pharmaceuticals Corporation | $1,337.28 | 2019-2024 | |
| Allergan, INC. | $1,014.94 | 2019-2021 | |
| Alexion Pharmaceuticals, INC. | $944.74 | 2019-2024 | Ultomiris |
| Amgen INC. | $802.07 | 2019-2024 | Aimovig, Uplizna |
| Lilly USA, LLC | $682.68 | 2019-2024 | Reyvow, Emgality, Amyvid |
| Argenx US, INC. | $577.60 | 2022-2024 | Vyvgart Hytrulo, Vyvgart |
| Genzyme Corporation | $566.00 | 2019-2024 | |
| Sk Life Science, INC. | $555.24 | 2020-2024 | Xcopri |
| Biogen, INC. | $499.59 | 2019-2023 | Vumerity |
| Csl Behring | $498.91 | 2019-2024 | Hizentra, Privigen |
| Genentech USA, INC. | $487.22 | 2019-2024 | Ocrevus, Enspryng |
| Teva Pharmaceuticals USA, INC. | $452.76 | 2019-2024 | Austedo Xr, Austedo |
| Lundbeck LLC | $449.15 | 2019-2024 | Vyepti, Rexulti |
Show all 75 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Raphael listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.